Gustave Roussy at the ESMO 2018 Congress

This year, the European Society for Medical Oncology (ESMO) will take place in Munich, Germany, from 19 to 23 October. It is Europe’s biggest cancer congress and the number of delegates increases year-on-year. Experts from all over the world visit the congress to share the latest clinical innovations in oncology. Around 20,000 delegates from 130 countries are expected to attend ESMO 2018.

Gustave Roussy will undoubtedly be one of the main stakeholders at this congress and specialists will present results during oral presentations, poster discussions and special symposia/posters.

Professor Fabrice André’s oral presentation of the results of the SOLAR-1 breast cancer study during the plenary session on Saturday, 20 October, is one of the highlights of the congress.

Renowned for their specialist knowledge, approximately ten experts will act as moderators in the oral sessions, symposia or discussions. Professor Karim Fizazi will officiate during a plenary session oral presentation on prostate cancer on Sunday 21 October.

Professor Alexander Eggermont, Gustave Roussy Director General, will be the speaker at a "special symposium" session focussing on therapeutic strategies for melanoma and outlining future plans for adjuvant immunotherapy treatments.

Gustave Roussy main presentations at ESMO 2018

• Advanced hormone-dependent breast cancer: Is the first medication to target a genome anomaly in the pipeline?
  Plenary Session | Pr Fabrice André | Read the Press Release

• Breast cancer: treatment compliance for women receiving tamoxifen?
  Oral | Dr Barbara Pistilli | Read ESMO Press Release

Change of practices

•  High-risk, localised prostate cancer: is it better to use a chemotherapy right from the outset?
  Oral | Pr Karim Fizazi

• Squamous cell carcinoma: Evidence of intensity-modulated radiotherapy
  Discussion | Dr Yungan Tao

• Efficacy of lenvatinib in Radioiodine-refractory Differentiated Thyroid Cancer
  Discussion | Dr Sophie Leboulleux

New and promising avenue in phase I trial

• Neuroendocrine tumours: Good perspective with an epigenetic target
  Discussion | Dr Antoine Hollebecque

Immunotherapy

• Metastatic renal cancer: a review of the use of Nivolumab in the management of cerebral metastases
  Discussion | Dr Ronan Flippot

• Treatment by immunotherapy: what is the link between efficacy and adverse events?
  Discussion | Dr Maria Kfoury

Expert in the management of sarcoma

• Rare peritoneal malignant disease: a cure is possible for patients with a dermoplastic small round cell tumour
  Discussion | Dr Charles Honoré

• Metastatic sarcomas: quality of life maintained with trabectedine
  Discussion | Dr Axel Le Cesne

Improve treatment toxicity and adverse events

• Physical activity and weight: Important parameters in combating chemo-induced neuropathies
  Discussion | Dr Margarida Matias
• Severe fatigue after breast cancer: Identify the patients at risk
  Discussion | Dr Ines Vaz Luis
• Adjuvant chemotherapy in breast cancer : Impact of physical activity on quality of life
  Discussion | Dr Antonio Di Meglio

▶ More information in our press kit